Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenolanib vs Midostaurin in Newly Diagnosed FLT3 Mutated AML
NCT03258931Phase 3Completed
- Sponsor
- AROG Pharmaceuticals, Inc.
- Start
- Aug 2018
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of crenolanib in acute myeloid leukemia (AML) (2 arms), sponsored by AROG Pharmaceuticals, Inc. Primary endpoint: Event-Free Survival at 5 years. Started Aug 2018; status: completed.
02
Drugs
crenolanib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03258931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03258931.